脂蛋白相关磷脂酶A_2与冠心病的相关性研究进展  

Research Progress of the Correlation between Lipoprotein Associated Phospholipase A_2 and Coronary Heart Disease

作　　者：王贤进 赵艳芳 

机构地区：[1]解放军第八一医院心血管内科,南京210002

出　　处：《医学综述》2016年第17期3363-3366,共4页Medical Recapitulate

基　　金：南京军区医药卫生科研基金(14ZD22)

摘　　要：脂蛋白相关磷脂酶A2(Lp-PLA2)是主要由巨噬细胞等炎性细胞分泌并与低密度脂蛋白结合,参与动脉粥样硬化形成的炎症过程。Lp-PLA2的活性受遗传和外环境等多因素影响,它是冠心病患者(尤其是中、高危患者)的独立危险预测因子。Lp-PLA2与颈动脉斑块及缺血性脑卒中有一定相关性。他汀类药物降低心血管事件与其降低Lp-PLA2活性呈正相关,Lp-PLA2抑制剂(darapladib)的Ⅲ期临床试验也未达主要临床终点。Lipoprotein associated phospholipase A2 （ Lp-PLA2 ） ,involved in the formation of atherosele- rosis,is an enzyme mainly produced by macrophages and attached＇ to low density lipopretein. Lp-PLA2 activity is influenced by genetic and environmental factors. Lp-PLA2 is an independent risk predictor for patients with coronary heart disease（ especially for patients with high risk）. There is a eertain correlation between Lp-PLA2 and carotid plaque and ischemie stroke. The deerease of Lp-PLA2 activity is positively correlated with the decrease of the cardiovascular events after treatment with statins. Phase three clinical trials of Lp-PLA2 inhibitors（daraoladib） did not reach the primary clinical end point.

关 键 词：冠心病 脂蛋白相关磷脂酶A2 脂蛋白相关磷脂酶A2抑制剂 

分 类 号：R541.4[医药卫生—心血管疾病]